Safety and efficacy of a new 3.3g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: A multicenter, randomized, double-blind, placebo-controlled study Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Colitis, Ulcerative
  • Mesalamine
  • Phenylhydrazines

abstract

  • Balsalazide disodium 1.1 g tablets administered as 3.3 g twice daily are effective, well tolerated and significantly better than placebo for improving signs and symptoms of mild-to-moderately-active UC. This new formulation with a reduced pill and dosing burden offers the potential to improve convenience and compliance in patients with active UC.

publication date

  • June 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/ajg.2009.83

PubMed ID

  • 19491859

Additional Document Info

start page

  • 1452

end page

  • 9

volume

  • 104

number

  • 6